Cancer:糖尿病不良控制能够增加去势抵抗性前列腺癌和转移的风险

2019-05-07 AlexYang MedSci原创

尽管糖尿病与前列腺癌(PC)风险呈现负相关关系,但是血糖控制对PC进展的的影响仍旧未知。最近,有研究人员在经历根治性前列腺切除(RP)男性糖尿病患者中,探究了血红蛋白A1c(HbA1c)和长期PC结果之间的相关性。研究共有1409名男性,其中699名患者(50%)HbA1c值<6.5%,631名(45%)患者的HbA1c值为6.5%到7.9%之间,79名(6%)患者的HbA1c值不小于8%。

尽管糖尿病与前列腺癌(PC)风险呈现负相关关系,但是血糖控制对PC进展的的影响仍旧未知。最近,有研究人员在经历根治性前列腺切除(RP)男性糖尿病患者中,探究了血红蛋白A1c(HbA1c)和长期PC结果之间的相关性。

研究共有1409名男性,其中699名患者(50%)HbA1c值<6.5%,631名(45%)患者的HbA1c值为6.5%到7.9%之间,79名(6%)患者的HbA1c值不小于8%。HbA1c值不小于8%的男性患者年纪跟小(P<0.001)并且是黑色人种的可能性大(P=0.13)。RP后平均跟踪调查的时间为6.8年(3.7-10.6年)。在多变量分析中,并未发现HbA1c与BCR之间具有相关性。然而,更高的HbA1c值与转移(HR,1.21;95%CI,1.02-1.44 [P=0.031])、CRP(HR, 1.27; 95% CI, 1.03-1.56 [P =0.023])相关。尽管统计学上不显著,更高的HbA1c值与PC特异性死亡率(HR, 1.24; 95% CI, 0.99-1.56 [P =0.067])和全因死亡率(HR, 1.09; 95% CI, 0.99-1.19 [P =0.058])存在相关的趋势。

最后,研究人员指出,在进行RP的糖尿病患者中,更高的HbA1c值与转移和CRPC相关。如果在更大的群体和更长的跟踪调查研究中被证实,未来的研究应该探究是否更高的血糖控制能够改善长期的PC结果。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665987, encodeId=cfbe166598eb6, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Mar 19 11:42:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342101, encodeId=338e134210158, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu May 09 04:42:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365884, encodeId=d933365884a7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 07 20:20:58 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040447, encodeId=5638104044ecc, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042422, encodeId=669910424225d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2020-03-19 yige2012
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665987, encodeId=cfbe166598eb6, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Mar 19 11:42:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342101, encodeId=338e134210158, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu May 09 04:42:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365884, encodeId=d933365884a7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 07 20:20:58 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040447, encodeId=5638104044ecc, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042422, encodeId=669910424225d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1665987, encodeId=cfbe166598eb6, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Mar 19 11:42:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342101, encodeId=338e134210158, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu May 09 04:42:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365884, encodeId=d933365884a7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 07 20:20:58 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040447, encodeId=5638104044ecc, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042422, encodeId=669910424225d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2019-05-07 一个字-牛

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1665987, encodeId=cfbe166598eb6, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Mar 19 11:42:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342101, encodeId=338e134210158, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu May 09 04:42:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365884, encodeId=d933365884a7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 07 20:20:58 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040447, encodeId=5638104044ecc, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042422, encodeId=669910424225d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2019-05-07 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1665987, encodeId=cfbe166598eb6, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Mar 19 11:42:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342101, encodeId=338e134210158, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37234, encryptionId=da143e23485, topicName=去势抵抗性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu May 09 04:42:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365884, encodeId=d933365884a7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 07 20:20:58 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040447, encodeId=5638104044ecc, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042422, encodeId=669910424225d, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue May 07 16:42:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2019-05-07 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

降低肿瘤转移和死亡风险近60%,前列腺癌新药获优先审评资格

拜耳(Bayer)公司和Orion公司宣布,美国FDA接受了该公司为雄激素受体(AR)拮抗剂darolutamide递交的新药申请(NDA),用于治疗非转移性去势抵抗性前列腺癌(nmCRPC)患者。

Prostate Cancer P D:转移去势难治性前列腺癌患者中sipuleucel-T单一疗法的PSA稳定性和总生存分析

Sipuleucel-T是一种自体细胞免疫疗法,该疗法获得了FDA的批准用于无症状或者症状微小的转移去势难治性前列腺癌(mCRPC)的治疗。IMPACT注册中心试验阐释了上述疗法的总生存增加了4.1个月,但是在PSA响应或者无进展生存的改善方面结果并不一致。基于一些因素,包括客观治疗的反应,Sipuleucel-T治疗在该类患者群体中规模缩小,尽管当前NCCN推荐使用。最近,有研究人员为了探索是否

Oncogenesis:ZFHX3对ERβ抑制细胞增殖是必不可少的

雌激素受体2(ESR2,也称之为ERβ)和锌指同源框3(ZFHX3,也称之为ATBF1)在小鼠中能够调控前列腺发育和抑制前列腺肿瘤的形成。ZFHX3对ESR1的功能是不可或缺的,ESR1与ESR2属于同一家族蛋白,但是在前列腺上皮中几乎不表达。ZFHX3怎样抑制前列腺致瘤过程仍旧不清楚。最近,有研究人员调查了是否ZFHX3和ERβ在抑制前列腺致瘤过程中存在互作。在C4-2B和LNCaP雄激素受体(

2019年AUA:临床前数据突显EPI-7386治疗前列腺癌的潜力

ESSA是一家专注于开发前列腺癌治疗新疗法的制药公司,近日宣布,将在2019年美国泌尿学会(AUA)年会上公布新一代N末端域雄激素受体抑制剂EPI-7386在去势抵抗前列腺癌模型中的有效性数据。

Prostate Cancer P D:改善前列腺活检患者风险评估和选择的预测模型研究

前列腺癌风险预测模型和多参数核磁共振成像(mpMRI)能够用于个性化的活检前风险评估。然而,双参数MRI(bpMRI)已经成为一种更加简单、更加迅速的MRI方法来减少花费并促进其在临床中的应用。bpMRI和风险模型怎样结合起来还是未知。最近,有研究人员基于bpMRI和临床参数为无活检历史的明显前列腺癌(sPCa)患者开发了一个预测模型。研究包括了876名无活检且具有临床疑似前列腺癌的男性(PSA&

Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查

美国食品和药物管理局(FDA)已接受新的药物申请审查,并给予darolutamide优先审查。